Shalini Sharp
Known title: DirectorCIK: 0001377202
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
Transaction History
| ONC | ▲ Buy | Grant | 18,980 | $0 | 6/11/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,659 | $0 | 5/21/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,435 | $0 | 5/22/2025 | View on chart |
| ONC | ▲ Buy | Grant | 10,985 | $0 | 5/21/2025 | View on chart |
| ONC | ▲ Buy | Grant | 8,151 | $0 | 9/30/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,100 | $0 | 5/17/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 1,106 | $157K | 5/17/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List
BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.